metoclopramide has been researched along with Genital Neoplasms, Female in 9 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Genital Neoplasms, Female: Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 9.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| " We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hydroxytryptamine3 (HT3) receptor antagonist, with those of a combination of high-dose metoclopramide, dexamethasone, diphenhydramine, and lorazepam (metoclopramide cocktail) in a randomized crossover study for the control of nausea and vomiting during cisplatin-containing chemotherapy." | 9.08 | Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. ( Chang, TC; Cheng, HH; Hsieh, F; Lai, CH; Li, CL; Michael, BJ; Soong, YK; Tseng, CJ, 1996) |
| ") was compared with a metoclopramide cocktail for the prevention of nausea and emesis." | 9.07 | An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( Frankendal, B; Hallén, C; Sorbe, B, 1994) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 5.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| " We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hydroxytryptamine3 (HT3) receptor antagonist, with those of a combination of high-dose metoclopramide, dexamethasone, diphenhydramine, and lorazepam (metoclopramide cocktail) in a randomized crossover study for the control of nausea and vomiting during cisplatin-containing chemotherapy." | 5.08 | Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. ( Chang, TC; Cheng, HH; Hsieh, F; Lai, CH; Li, CL; Michael, BJ; Soong, YK; Tseng, CJ, 1996) |
| ") was compared with a metoclopramide cocktail for the prevention of nausea and emesis." | 5.07 | An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( Frankendal, B; Hallén, C; Sorbe, B, 1994) |
| "This pilot randomized study compared MDL 72,222, a highly selective 5-HT3 receptor antagonist, with a high-dose metoclopramide regimen (HDM) for chemotherapy-induced nausea and vomiting." | 5.07 | Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen. ( Barrett, RJ; Hahne, WF; Heck, K; Homesley, HD; Lentz, SS; Lovelace, JV; McLees, B; Woodlief, L, 1993) |
| "Metoclopramide was given intravenously 4 times during a 6-hour period (1/2 h before and 1 1/2, 3 1/2 and 5 1/2 h after cytostatic treatment) in a total dose of 1, 2, 4, 6, or 8 mg/kg." | 1.27 | High-dose metoclopramide in the treatment of cis-platinum induced emesis. A dose-finding study. ( Danneskiold-Samsøe, P; Hauksson, A; Tropé, C, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Framarino dei Malatesta, M | 1 |
| Veneziano, M | 1 |
| Fiorelli, C | 1 |
| Bandiera, AF | 1 |
| Yacoub, M | 1 |
| Toccaceli Blasi, MR | 1 |
| Marzetti, L | 1 |
| Sorbe, B | 1 |
| Hallén, C | 1 |
| Frankendal, B | 1 |
| Homesley, HD | 1 |
| Hahne, WF | 1 |
| McLees, B | 1 |
| Heck, K | 1 |
| Barrett, RJ | 1 |
| Lentz, SS | 1 |
| Woodlief, L | 1 |
| Lovelace, JV | 1 |
| Chang, TC | 1 |
| Hsieh, F | 1 |
| Lai, CH | 1 |
| Tseng, CJ | 1 |
| Cheng, HH | 1 |
| Li, CL | 1 |
| Michael, BJ | 1 |
| Soong, YK | 1 |
| Malone, JM | 1 |
| Christensen, CW | 1 |
| Yashinsky, D | 1 |
| Malviya, VK | 1 |
| Deppe, G | 1 |
| Hayashi, Y | 1 |
| Iwasaka, T | 1 |
| Hachisuga, T | 1 |
| Fukuda, K | 1 |
| Tanaka, T | 1 |
| Matsuo, N | 1 |
| Sugimori, H | 1 |
| Krebs, HB | 1 |
| Myers, MB | 1 |
| Wheelock, JB | 1 |
| Goplerud, DR | 1 |
| Benrubi, GI | 1 |
| Norvell, M | 1 |
| Nuss, RC | 1 |
| Robinson, H | 1 |
| Tropé, C | 1 |
| Danneskiold-Samsøe, P | 1 |
| Hauksson, A | 1 |
7 trials available for metoclopramide and Genital Neoplasms, Female
| Article | Year |
|---|---|
Ondansetron in chemotherapy-induced emesis. Our experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas | 1995 |
An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Genita | 1994 |
Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen.
Topics: Adult; Aged; Antiemetics; Cisplatin; Diphenhydramine; Drug Therapy, Combination; Female; Genital Neo | 1993 |
Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Drug Therapy, Combin | 1996 |
Prochlorperazine and transdermal scopolamine added to a metoclopramide antiemetic regimen. A controlled comparison.
Topics: Administration, Cutaneous; Cisplatin; Female; Genital Neoplasms, Female; Humans; Infusions, Intraven | 1990 |
Combination antiemetic therapy in cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Ge | 1985 |
The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Me | 1985 |
2 other studies available for metoclopramide and Genital Neoplasms, Female
| Article | Year |
|---|---|
[Antiemetic efficacy of high-dose metoclopramide, diphenhydramine, methylprednisolone and diazepam on chemotherapy-induced emesis in gynecological malignancy].
Topics: Adult; Aged; Cisplatin; Diazepam; Diphenhydramine; Drug Therapy, Combination; Female; Genital Neopla | 1988 |
High-dose metoclopramide in the treatment of cis-platinum induced emesis. A dose-finding study.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Fem | 1985 |